Needham analyst David Saxon has maintained their neutral stance on SGHT stock, giving a Hold rating on October 22.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Saxon has given his Hold rating due to a combination of factors including Sight Sciences’ recent financial performance and future prospects. The company’s third-quarter results for 2025 exceeded expectations, with revenue surpassing consensus estimates and management raising its revenue guidance for the year. This positive performance was largely driven by growth in the Surgical Glaucoma segment, which benefited from an increase in the number of ordering accounts and favorable average selling prices.
Despite these positive developments, Saxon remains cautious. While the Dry Eye segment has shown potential, particularly with new coverage from two MACs, there is still uncertainty regarding the near-term estimates. Saxon prefers to maintain a Hold rating until there is greater confidence in the potential for upside in the company’s financial outlook. This cautious approach reflects a balanced view of the company’s current achievements and the uncertainties that lie ahead.
In another report released on October 22, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $5.50 price target.